跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,739 条关于
“Rev-56”
全部
3,739
临床试验
2,129
药物
570
机构
134
资讯
906
上个月
Revagenix Doses First Participant in Phase 1 Trial of Rev-56, a First-in-Class Inhaled Anti-Pseudomonal Therapy for Non-CF Bronchiectasis
去年
Praxis Precision Medicines Reports 56% Seizure Reduction with Vormatrigine Despite Stock Decline
去年
ImmunityBio Launches Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma
去年
ImmunityBio Initiates Phase 1 Trial of CD19 t-haNK Cell Therapy for Non-Hodgkin Lymphoma
去年
Savolitinib Plus TAGRISSO® Shows 56% Response Rate in MET-High Lung Cancer, HUTCHMED Reports
去年
AstraZeneca's Camizestrant Shows 56% Reduction in Breast Cancer Progression Risk Using Blood Test-Guided Treatment
去年
Neuros Medical Secures $56 Million Series D to Commercialize FDA-Approved Post-Amputation Pain Treatment
上个月
Semaglutide Linked to 56% Lower Risk of Adult-Onset Seizures in Type 2 Diabetes Patients
去年
Philippine Senator Urges Fast-Track Approval of Takeda's TAK-003 Dengue Vaccine Amid 56% Case Surge
2个月前
Market Rotation Fuels Biotech Surge as AI Trade Falters; Definium Therapeutics Rises on Anxiety Disorder Catalyst
第 1 页,共 91 页
上一页
下一页